Published in:
01-01-2010 | Letter to the Editors
Intrathecal levels of IL-6 in Alzheimer’s disease
Author:
Kurt A. Jellinger
Published in:
Journal of Neurology
|
Issue 1/2010
Login to get access
Excerpt
In a recent study, Galimberti et al. [
2] reported a significant increase of IL-11 disease (AD
n = 43) and frontotomporal lobar degeneration (FTLD
n = 24) in patients with Alzheimer’s disease in comparison to age-matched controls (
n = 30). At the same time, IL-6 showed only a non-significant increase in demented subjects. Measurement of CSF IL-6 levels in AD have revealed contradictory results—unchanged [
3,
5] and increased [
1,
8,
9]. In our personal studies in a cohort of 169 aged subjects, we found probable AD (
n = 27), non-AD dementia (
n = 24, including FTLD
n = 10 and vascular dementia
n = 5), and other CNS disorders without cognitive impairment (infections, vascular, neurodegenerative diseases
n = 69). A specific immunoabsorbent assay (ELISA, R&D Systems, Minneapolis, MN, USA) revealed a significant increase of IL-6 immunoreactivity in CSF of both AD and non-AD dementias compared to controls (
P < 0.03), despite broad overlap. AD patients with late onset (>65 years) had significantly higher values than those with early onset (
P < 0.05), but, as in Galimberti’s cohort, there were no correlations of CSF IL-6 with age, MMSE scores, disease duration, or CSF Aβ-42 and T-tau [
4,
6]. These data and increased CSL IL-6 levels in hypertensive encephalopathy [
7] suggest that it may reflect IL-mediated immunologic phenomena in the course of neurodegenerative processes. …